Phase I and pharmacokinetic study of sunitinib in pediatric patients with refractory solid tumors: a children's oncology group study. - Wikidata - wikimedia - TriplyDB

Phase I and pharmacokinetic study of sunitinib in pediatric patients with refractory solid tumors: a children's oncology group study.

Phase I and pharmacokinetic study of sunitinib in pediatric patients with refractory solid tumors: a children's oncology group study.

http://www.wikidata.org/entity/Q33395853

about

Present Advances and Future Perspectives of Molecular Targeted Therapy for Osteosarcoma Receptor tyrosine kinases: Characterisation, mechanism of action and therapeutic interests for bone cancers Early phase clinical trials of anticancer agents in children and adolescents - an ITCC perspective.Off-label use of targeted therapies in osteosarcomas: data from the French registry OUTC'S (Observatoire de l'Utilisation des Thérapies Ciblées dans les Sarcomes).Tolerability and pharmacokinetic profile of a sunitinib powder formulation in pediatric patients with refractory solid tumors: a Children's Oncology Group study Cardiovascular disease in adult survivors of childhood cancer.Combining targeted agents with modern radiotherapy in soft tissue sarcomas.Growth plate abnormalities in pediatric cancer patients undergoing phase 1 anti-angiogenic therapy: a report from the Children's Oncology Group Phase I Consortium.Challenges of clinical trial design for targeted agents against pediatric leukemias.Circulating endothelial progenitor cells in castration resistant prostate cancer: a randomized, controlled, biomarker study.Managing chemotherapy-related cardiotoxicity in survivors of childhood cancers.Clinical development of VEGF signaling pathway inhibitors in childhood solid tumors.Molecular profiling of childhood cancer: Biomarkers and novel therapies Ontogeny and sorafenib metabolism.The Tyrosine Kinase Inhibitor Sunitinib Affects Ovulation but Not Ovarian Reserve in Mouse: A Preclinical Study Neurotoxicity of biologically targeted agents in pediatric cancer trials The combination of novel targeted molecular agents and radiation in the treatment of pediatric gliomas.Preclinical Evidence for the Use of Sunitinib Malate in the Treatment of Plexiform Neurofibromas.A review of targeted therapies evaluated by the pediatric preclinical testing program for osteosarcoma.Phase I pharmacokinetic and pharmacodynamic study of pazopanib in children with soft tissue sarcoma and other refractory solid tumors: a children's oncology group phase I consortium report.Phase II evaluation of sunitinib in the treatment of recurrent or refractory high-grade glioma or ependymoma in children: a children's Oncology Group Study ACNS1021.Optimal management of Ewing sarcoma family of tumors: recent developments in systemic therapy.Drugs targeting the bone microenvironment: new therapeutic tools in Ewing's sarcoma?The potential of sunitinib as a therapy in ovarian cancer.Targeted therapies for bone sarcomas.Targeted therapy in pediatric low-grade glioma.The angiogenic asset of soft tissue sarcomas: a new tool to discover new therapeutic targets.Targeted approaches to childhood cancer: progress in drug discovery and development.Pericytes in sarcomas of bone.Physiological, Tumor, and Metastatic Niches: Opportunities and Challenges for Targeting the Tumor Microenvironment.Benefit, Risk, and Outcomes in Drug Development: A Systematic Review of Sunitinib.Drugs in early clinical development for the treatment of osteosarcoma.A comparison of safety and efficacy of cytotoxic versus molecularly targeted drugs in pediatric phase I solid tumor oncology trials.Conventional chemotherapy and perspectives for molecular-based oncological treatment in pediatric hemispheric low-grade gliomas.Lessons learned from adult clinical experience to inform evaluations of VEGF pathway inhibitors in children with cancer.Anti-angiogenesis target therapy for advanced osteosarcoma (Review).MAPK/ERK Signaling in Osteosarcomas, Ewing Sarcomas and Chondrosarcomas: Therapeutic Implications and Future Directions.Bone sarcomas: from biology to targeted therapies.Targeting FLT3 Signaling in Childhood Acute Myeloid Leukemia.Biomechanical regulation of drug sensitivity in an engineered model of human tumor.

P2860

Q26750631-AF181000-02BF-434D-940C-50ABCBF5CD0D Q28082793-0C1FBD98-D3A5-4C75-8F16-BC2CD64AC36F Q30234441-D39D4BD3-6A46-4C51-BE25-4028A72CB7AD Q31018689-A7AB8021-CE25-4501-898B-A865E622E267 Q33559444-6A1F36AE-2509-47DF-971D-883BA1DEEDA6 Q34042984-AFFE7B25-C22F-408A-90B5-62A7B0A99FD8 Q34396047-4E937BDA-AD47-4480-B164-8FA06008AC13 Q34543413-9CE97710-47D6-410C-98C6-AC68E0A34C77 Q34839887-F837E383-6615-4F97-AE8D-25AE2A3AB902 Q35155251-81EE03F3-F631-4AEB-9566-FBA009471B35 Q35562745-9A11CBF6-D798-4660-96A0-AED02AC882F6 Q35599819-BC7C9320-C75B-40FF-881F-13775229CC28 Q36250783-9569B1EF-6766-472B-9282-7996332F35DE Q36375706-4356CA32-68D6-42D1-9F39-58FBC7F08AF2 Q36757329-17A96F70-9A65-45FB-86ED-600E35B6A4AF Q36766221-E69DBDDA-D779-42AB-A2F7-5923ED1B81E7 Q36833480-B5114CEE-78CF-4FCE-B144-B0E004A27999 Q36887270-395EAF10-E483-4567-844D-D6F6FB54A774 Q36888962-21534701-4E9D-4F52-8100-520EB8AA830F Q37085863-671BEE5E-80AD-4CC0-B30F-2533729C1C35 Q37094908-D41F2CCE-3A29-4003-8B1F-8932B20FBE8C Q38113988-6A493259-605B-42FC-8A4D-2D0595D669EF Q38129954-E07A5365-050C-4552-B719-C2D351FE47A0 Q38144166-D3178AAC-0DA7-46D1-AFEE-AA4279B6E95E Q38178277-2314AAD0-0B32-4663-8B19-4490EDCE2A5C Q38194055-E0782F73-12DB-4B02-9FDF-68F808159189 Q38252537-C017EC42-F12C-4243-A48E-94B9733D63F7 Q38404462-D924F1A8-2F19-4299-BB25-2B46B65EAAED Q38528174-1C7FFE95-59F5-412E-8981-CDA9C1E54E52 Q38582873-EE2E4332-4ECE-426B-99F1-96DEDB8A8FF5 Q38627885-27837CC4-EF5E-4B42-BDA3-A1DB3821C022 Q38955517-D400898C-F7FD-4408-9C2F-5745340D3057 Q38961012-B8B66BC8-15A3-4FC3-91E8-F1396B2F0F77 Q38962187-A57FAD3D-A4D9-49DD-84AC-B7C57CA3BFC9 Q39204706-2F96DE0A-C447-4BDC-A3B3-23A5F23D38CC Q39401628-C6190822-0194-4416-A472-807970FFAD78 Q39618772-4994AB9D-6874-4CCB-B996-0BF436FA29C1 Q41923624-1B1E8D27-28DE-4BF2-A790-C2DF821DD1B2 Q47150923-69C646C8-A0F1-4B2C-89EA-BEDAC51D8584 Q47436328-D286B794-DC93-4D59-9AF0-6A16241AFF11

P2860

Phase I and pharmacokinetic study of sunitinib in pediatric patients with refractory solid tumors: a children's oncology group study.

http://www.wikidata.org/entity/Q33395853

description

2011 nî lūn-bûn

@nan

2011 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Phase I and pharmacokinetic st ...... ildren's oncology group study.

@ast

Phase I and pharmacokinetic st ...... ildren's oncology group study.

@en

type

label

Phase I and pharmacokinetic st ...... ildren's oncology group study.

@ast

Phase I and pharmacokinetic st ...... ildren's oncology group study.

@en

prefLabel

Phase I and pharmacokinetic st ...... ildren's oncology group study.

@ast

Phase I and pharmacokinetic st ...... ildren's oncology group study.

@en

P1433

Q33395853-CE1A670E-0E0A-4A02-8500-6ACC43B8819A

P1476

Q33395853-7B26D334-A2FB-4A49-BC81-045D1A98BED0

P2093

Q33395853-04355A2E-A37D-42EC-B645-2B79F279FED1

Q33395853-0EE88D66-FEAE-481E-BE72-DB5DD7FB4C61

Q33395853-1A30739D-C650-49FE-AB9A-C2FCA4CBCDF7

Q33395853-59FEC64D-2283-4EDB-B861-BD8BEF61D2EE

Q33395853-85226DFA-519A-41E1-B748-5BDBB36C135B

Q33395853-ADFAFAD3-9E9F-405B-A011-33BCA66C1796

Q33395853-B9E72EC6-D74A-4E40-9268-B4E75F604867

Q33395853-BB7E8D17-D058-4BBE-A85A-EA083A24F887

Q33395853-D418B3F1-EB6C-4F0A-BDAB-FF44FF39E330

Q33395853-DFCC1103-D122-49CE-AA08-9D8561585A68

P2860

Q33395853-00A57758-722E-4FA8-9867-0216CA09984E

Q33395853-01D8CF47-3073-4430-9253-12507BAF88D8

Q33395853-0C39F3A9-B87D-49B3-BCDF-59A643B4F289

Q33395853-0D8FC50F-E902-4402-AF32-DD2F8E5FBC2A

Q33395853-0F909B7F-D630-4DE8-8ADA-77C86969B00B

Q33395853-1317EFFF-BEBB-4652-B0C3-CFA7D674C984

Q33395853-26683308-0144-48E9-A9EC-FC5B74516914

Q33395853-2E890304-592B-46B1-A47C-A722B74D5109

Q33395853-34ECB7B1-DA46-467B-A59E-34EEFAF15764

Q33395853-4C230FF0-E6D6-4683-8665-5592CD57EB1D

P304

Q33395853-39BE1EA6-455D-42CF-86F4-865E77B5801A

P31

Q33395853-609BEF3A-0F31-4353-8076-D63E5EB159F0

P356

Q33395853-ADF4A64E-3E89-4412-9DBB-27A1CEACA0F5

P407

Q33395853-5D509F5E-D886-4972-BC4D-94EB6800B9BA

P433

Q33395853-FF713753-6E60-469C-8DE5-21327F810DCD

P478

Q33395853-5A80B211-2696-48AD-870E-E9AA1308DC8F

P50

Q33395853-CBF97C54-C8CF-43AB-A206-00B782678C41

P577

Q33395853-DFD0290B-370D-4EE0-88F6-AC8249C6EE18

P698

Q33395853-6A73C893-4F4A-4851-AF60-2D3E9D78DC5C

P932

Q33395853-F7710B02-894F-433B-AF82-E17495D1525B

P356

1078-0432.CCR-11-0237

P1433

Clinical Cancer Research

P1476

Phase I and pharmacokinetic st ...... ildren's oncology group study.

@en

P2093

Ashish M Ingle

http://www.w3.org/2001/XMLSchema#string

Bing Wu

http://www.w3.org/2001/XMLSchema#string

Charlotte H Ahern

http://www.w3.org/2001/XMLSchema#string

Holcombe E Grier

http://www.w3.org/2001/XMLSchema#string

Joel M Reid

http://www.w3.org/2001/XMLSchema#string

Julia Glade-Bender

http://www.w3.org/2001/XMLSchema#string

Percy Ivy

http://www.w3.org/2001/XMLSchema#string

Peter C Adamson

http://www.w3.org/2001/XMLSchema#string

Steven G Dubois

http://www.w3.org/2001/XMLSchema#string

Suzanne Shusterman

http://www.w3.org/2001/XMLSchema#string

P2860

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Endoglin (CD105): a powerful therapeutic target on tumor-associated angiogenetic blood vessels

Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer.

Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study.

Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC stu

A phase I, dose-finding study of sunitinib in combination with irinotecan in patients with advanced solid tumours.

Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas.

P304

5113-5122

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-11-0237

http://www.w3.org/2001/XMLSchema#string

P407

P433

15

http://www.w3.org/2001/XMLSchema#string

P478

17

http://www.w3.org/2001/XMLSchema#string

P50

P577

2011-06-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21690570

http://www.w3.org/2001/XMLSchema#string

P932

3149978

http://www.w3.org/2001/XMLSchema#string